Standout Papers

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneo... 2006 2026 2012 2019 853
  1. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) (2006)
    Madeleine Duvic, Xiao Ni et al. Blood

Immediate Impact

3 by Nobel laureates 15 from Science/Nature 84 standout
Sub-graph 1 of 20

Citing Papers

Naturally occurring T cell mutations enhance engineered T cell therapies
2024 StandoutNature
Sequential C–F bond functionalizations of trifluoroacetamides and acetates via spin-center shifts
2021 StandoutScience
1 intermediate paper

Works of Xiao Ni being referenced

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
2006 Standout
Selective Induction of Apoptosis by Histone Deacetylase Inhibitor SAHA in Cutaneous T-Cell Lymphoma Cells: Relevance to Mechanism of Therapeutic Action
2005
and 1 more

Author Peers

Author Last Decade Papers Cites
Xiao Ni 865 687 571 1077 702 41 2.2k
Takashi Kakinuma 1090 1113 569 553 329 34 2.6k
Barbara White 273 1135 449 443 645 50 2.4k
Raquel Villuendas 331 357 1080 804 1141 47 2.4k
Michał Marzec 174 777 957 1003 526 41 2.3k
Madeleine Duvic 698 554 188 298 461 30 1.4k
Floyd E. Fox 334 489 788 691 307 57 1.9k
Keld Kaltoft 322 671 604 472 242 30 1.6k
András Schaffer 240 1116 412 681 262 42 2.1k
Meg R. Gerstenblith 320 254 913 1210 241 35 2.1k
Carsten Weishaupt 416 850 1324 931 165 59 2.6k

All Works

Loading papers...

Rankless by CCL
2026